<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36232365</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms231911063</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a heterogeneous disease, both in its onset phenotype and in its rate of progression. The aim of this study was to establish whether the dysfunction of the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) measured through cerebrospinal fluid (CSF) proteins and the albumin-quotient (QAlb) are related to the speed of disease progression. An amount of 246 patients diagnosed with ALS were included. CSF and serum samples were determined biochemically for different parameters. Survival analysis based on phenotype shows higher probability of death for bulbar phenotype compared to spinal phenotype (<i>p</i>-value: 0.0006). For the effect of CSF proteins, data shows an increased risk of death for spinal ALS patients as the value of CSF proteins increases. The same model replicated for CSF albumin yielded similar results. Statistical models determined that the lowest cut-off value for CSF proteins able to differentiate patients with a good prognosis and worse prognosis corresponds to CSF proteins &#x2265; 0.5 g/L (<i>p</i>-value: 0.0189). For the CSF albumin, the QAlb &#x2265;0.65 is associated with elevated probability of death (<i>p</i>-value: 0.0073). High levels of QAlb are a bad prognostic indicator for the spinal phenotype, in addition to high CSF proteins levels that also act as a marker of poor prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assialioui</LastName><ForeName>Abdelilah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Department of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Consorci Sanitari Alt Pened&#xe8;s-Garraf, 08720 Vilafranca del Pened&#xe8;s, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropathology Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Department of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Diseases and Neurogenetics Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9888-8754</Identifier><AffiliationInfo><Affiliation>Neuropathology Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;s-Benito</LastName><ForeName>Pol</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3000-0338</Identifier><AffiliationInfo><Affiliation>Neuropathology Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Department of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Diseases and Neurogenetics Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Fundaci&#xf3; Catalana d'ELA Miquel Valls</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>Retos todos unidos contra la ELA</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>Proyecto DGeneracion conexiones con sentido</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002556">Cerebrospinal Fluid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002556" MajorTopicYN="N">Cerebrospinal Fluid Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">albumin</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">prognostic</Keyword><Keyword MajorTopicYN="N">spinal ALS</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36232365</ArticleId><ArticleId IdType="pmc">PMC9570498</ArticleId><ArticleId IdType="doi">10.3390/ijms231911063</ArticleId><ArticleId IdType="pii">ijms231911063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. New England Journal of Medicine. Volume 377. Massachussetts Medical Society; Waltham, MA, USA: 2017. Amyotrophic lateral sclerosis; pp. 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P., Byrne S., Jordan N., Gallagher L., Wynne B., O&#x2019;brien C., Phukan J., Lynch C., Pender N., Hardiman O. Cognitive changes predict functional decline in ALS A population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S., Heverin M., Elamin M., Bede P., Lynch C., Kenna K., Maclaughlin R., Walsh C., Al Chalabi A., Hardiman O. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:699&#x2013;708. doi: 10.1002/ana.23969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23969</ArticleId><ArticleId IdType="pubmed">23836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J., Stahl D., Wijesekera L., Galtrey C., Shaw C.E., Leigh P.N., Al-Chalabi A. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS ONE. 2009;4:e7107. doi: 10.1371/journal.pone.0007107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007107</ArticleId><ArticleId IdType="pmc">PMC2741575</ArticleId><ArticleId IdType="pubmed">19771164</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.J., Debray T.P.A., Visser A.E., van Eijk R.P.A., Rooney J.P.K., Calvo A., Martin S., McDermott C.J., Thompson A.G., Pinto S., et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Hernandez-Ontiveros D.G., Rodrigues MC O., Haller E., Frisina-Deyo A., Mirtyl S., Sallot S., Saporta S., Borlongan C.V., Sanberg P.R. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128. doi: 10.1016/j.brainres.2012.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Rodrigues M.C.O., Hernandez-Ontiveros D.G., Louis M.K., Willing A.E., Borlongan C.V., Sanberg P.R. Amyotrophic lateral sclerosis: A neurovascular disease. Brain Res. 2011;1398:113&#x2013;125. doi: 10.1016/j.brainres.2011.04.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.04.049</ArticleId><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Spliet WG M., Aronica E., Ramkema M., Witmer A.N., Schlingemann R.O., De Jong JM B.V., Troost D. Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: Altered expression in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2004;30:351&#x2013;359. doi: 10.1111/j.1365-2990.2003.00543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2003.00543.x</ArticleId><ArticleId IdType="pubmed">15305980</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.A., Sengillo J.D., Bell R.D., Wang J., Zlokovic B.V. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J. Cereb. Blood Flow Metab. 2012;32:1841&#x2013;1852. doi: 10.1038/jcbfm.2012.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.113</ArticleId><ArticleId IdType="pmc">PMC3463878</ArticleId><ArticleId IdType="pubmed">22850407</ArticleId></ArticleIdList></Reference><Reference><Citation>Es MA Van Hardiman O., Chio A., Al-chalabi A., Pasterkamp R.J., Veldink J.H., Van Den Berg L.H. Seminar Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;390:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P., Dom&#xed;nguez R., Colomina M.J., Llorens F., Povedano M., Ferrer I. Erratum: Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: Cerebrospinal fluid levels as a prognosis marker of disease progression. Aging. 2021;13:23871. doi: 10.18632/aging.203667.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203667</ArticleId><ArticleId IdType="pmc">PMC8580344</ArticleId><ArticleId IdType="pubmed">34738920</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter M.K., Gendron T.F. Biomarkers for amyotrophic lateral sclerosis and frontotemporal dementia associated with hexanucleotide expansion mutations in C9orf72. Front. Neurol. 2018;9:1&#x2013;9. doi: 10.3389/fneur.2018.01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01063</ArticleId><ArticleId IdType="pmc">PMC6289985</ArticleId><ArticleId IdType="pubmed">30568632</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T., Beck M., Giess R., Puls I., Naumann M., Toyka K.V. Disease progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle Nerve. 2002;25:709&#x2013;714. doi: 10.1002/mus.10090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiloff R.J., McGregor B., Thompson E., Blackwood W., Paul E. Motor neurone disease with elevated cerebrospinal fluid protein. J. Neurol. Neurosurg. Psychiatry. 1980;43:390&#x2013;396. doi: 10.1136/jnnp.43.5.390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.43.5.390</ArticleId><ArticleId IdType="pmc">PMC490564</ArticleId><ArticleId IdType="pubmed">7420088</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi A., Abbruzzese G., Arata L., Cocito L., Vische M. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J. Neurol. 1984;231:75&#x2013;78. doi: 10.1007/BF00313720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313720</ArticleId><ArticleId IdType="pubmed">6737012</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris F.H., Burns W., Mukai E., Norris H. Spinal Fluid Cells and Protein in Amyotrophic Lateral Sclerosis. Arch. Neurol. 1993;50:489&#x2013;491. doi: 10.1001/archneur.1993.00540050041012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540050041012</ArticleId><ArticleId IdType="pubmed">8489404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Guan Y., Liu M., Li X., Shen D., Li D., Cui B., Fang J., Ding Q., et al. Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Dharmadasa T., Malaspina A., Shaw P.J., Talbot K., Turner M.R., Thompson A.G. Creatine kinase and prognosis in amyotrophic lateral sclerosis: A literature review and multi-centre cohort analysis. J. Neurol. 2022 doi: 10.1007/s00415-022-11195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11195-8</ArticleId><ArticleId IdType="pmc">PMC9467954</ArticleId><ArticleId IdType="pubmed">35614165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H., Ho W.Y., Chang J., Ling S. Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: Cause, consequence, or epiphenomenon? FEBS J. 2021 doi: 10.1111/febs.16175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16175</ArticleId><ArticleId IdType="pubmed">34469619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozga J., Piatek T., Ma&#x142;kowski P. Human albumin: Old, new, and emerging applications. Ann. Transplant. 2013;18:205&#x2013;217. doi: 10.12659/AOT.889188.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AOT.889188</ArticleId><ArticleId IdType="pubmed">23792522</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;ssmuth S.D., Sperfeld A.D., Ludolph A.C., Tumani H. Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis. Neurochem. Res. 2010;35:1071&#x2013;1074. doi: 10.1007/s11064-010-0156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-010-0156-9</ArticleId><ArticleId IdType="pubmed">20333464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N., Tiloca C., Mencacci N.E., Morelli C., Doretti A., Rusconi D., Colombrita C., Sangalli D., Verde F., Finelli P., et al. Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. J. Neurol. 2013;260:85&#x2013;92. doi: 10.1007/s00415-012-6589-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6589-0</ArticleId><ArticleId IdType="pmc">PMC4196642</ArticleId><ArticleId IdType="pubmed">22752089</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.A., Sengillo J.D., Sullivan J.S., Henkel J.S., Appel S.H., Zlokovic B.V. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111&#x2013;120. doi: 10.1007/s00401-012-1039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Spector R., Robert Snodgrass S., Johanson C.E. A balanced view of the cerebrospinal fluid composition and functions: Focus on adult humans. Exp. Neurol. 2015;273:57&#x2013;68. doi: 10.1016/j.expneurol.2015.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.027</ArticleId><ArticleId IdType="pubmed">26247808</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibbling G., Link H., &#xd6;hman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Investig. 1977;37:385&#x2013;390. doi: 10.3109/00365517709091496.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365517709091496</ArticleId><ArticleId IdType="pubmed">337459</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B., Ku&#x17a;ma-Kozakiewicz M. Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurol. Sci. 2020;41:1115&#x2013;1124. doi: 10.1007/s10072-019-04201-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId><ArticleId IdType="pubmed">31897946</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisenhammer F., Bartos A., Egg R., Gilhus N.E., Giovannoni G., Rauer S., Sellebjerg F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur. J. Neurol. 2006;13:913&#x2013;922. doi: 10.1111/j.1468-1331.2006.01493.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01493.x</ArticleId><ArticleId IdType="pubmed">16930354</ArticleId></ArticleIdList></Reference><Reference><Citation>McCudden C.R., Brooks J., Figurado P., Bourque P.R. Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data. Clin. Chem. 2017;63:1856&#x2013;1865. doi: 10.1373/clinchem.2017.278267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.278267</ArticleId><ArticleId IdType="pubmed">29021324</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott N.J., Friedman A. Overview and introduction: The blood-brain barrier in health and disease. Epilepsia. 2012;53((Suppl. 6)):1&#x2013;6. doi: 10.1111/j.1528-1167.2012.03696.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2012.03696.x</ArticleId><ArticleId IdType="pmc">PMC3625728</ArticleId><ArticleId IdType="pubmed">23134489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross P.M. Circumventricular organ capillaries. Prog. Brain Res. 1992;91:219&#x2013;233. doi: 10.1016/S0079-6123(08)62338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(08)62338</ArticleId><ArticleId IdType="pubmed">1410407</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross P.M., Weindl A., Weindl K.M. Peering through the windows of the brain. J. Cereb. Blood Flow Metab. 1987;7:663&#x2013;672. doi: 10.1038/jcbfm.1987.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.1987.120</ArticleId><ArticleId IdType="pubmed">2891718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels A.L., Kortekaas R., Bart J., Willemsen A.T., de Klerk O.L., de Vries J.J., van Oostrom J.C., Leenders K.L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neurobiol. Aging. 2009;30:1818&#x2013;1824. doi: 10.1016/j.neurobiolaging.2008.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.02.002</ArticleId><ArticleId IdType="pubmed">18358568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji K.-A., Eu M.Y., Kang S.-H., Gwag B.J., Jou I., Joe E.-H. Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia. 2008;56:1039&#x2013;1047. doi: 10.1002/glia.20677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20677</ArticleId><ArticleId IdType="pubmed">18381656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuntner C., Bankstahl J.P., Bankstahl M., Stanek J., Wanek T., Stundner G., Langer O. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging. 2010;37:942&#x2013;953. doi: 10.1007/s00259-009-1332-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1332-5</ArticleId><ArticleId IdType="pmc">PMC3690672</ArticleId><ArticleId IdType="pubmed">20016890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartanusz V., Jezova D., Alajajian B., Digicaylioglu M. The blood-spinal cord barrier: Morphology and clinical implications. Ann. Neurol. 2011;70:194&#x2013;206. doi: 10.1002/ana.22421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22421</ArticleId><ArticleId IdType="pubmed">21674586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G.N., Evans R.A., Banks D.B., Mesev E.V., Miller D.S., Cannon R.E. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model. Neurosci. Lett. 2017;639:103&#x2013;113. doi: 10.1016/j.neulet.2016.12.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.12.049</ArticleId><ArticleId IdType="pmc">PMC5278641</ArticleId><ArticleId IdType="pubmed">28011392</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay R.K. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed. Res. Int. 2014;2014:869269. doi: 10.1155/2014/869269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/869269</ArticleId><ArticleId IdType="pmc">PMC4127280</ArticleId><ArticleId IdType="pubmed">25136634</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.Y., Cai Z.Y., Sun X.H., Shen D.C., Yang X.Z., Liu M.S., Cui L.Y. Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia. Neurol. Sci. 2022;43:3201&#x2013;3210. doi: 10.1007/s10072-021-05731-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05731-z</ArticleId><ArticleId IdType="pubmed">34826032</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T., Vlad B., Gaur N., Stubendorff B., Grosskreutz J. Blood-brain barrier disruption is not associated with disease aggressiveness in amyotrophic lateral sclerosis. Front. Neurosci. 2021;15:656456. doi: 10.3389/fnins.2021.656456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.656456</ArticleId><ArticleId IdType="pmc">PMC8586537</ArticleId><ArticleId IdType="pubmed">34776835</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M.D., Zhao Z., Montagne A., Nelson A.R., Zlokovic B.V. From physiology to disease and back. Physiol. Rev. 2019;99:21&#x2013;78. doi: 10.1152/physrev.00050.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00050.2017</ArticleId><ArticleId IdType="pmc">PMC6335099</ArticleId><ArticleId IdType="pubmed">30280653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci. 2011;12:723&#x2013;738. doi: 10.1038/nrn3114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3114</ArticleId><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Lee J.D., Woodruff T.M., Henderson R.D. The peripheral immune system and amyotrophic lateral sclerosis. Front. Neurol. 2020;11:279. doi: 10.3389/fneur.2020.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M.C., Couch Y., Sibson N., Turner M.R. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2013;53:34&#x2013;41. doi: 10.1016/j.mcn.2012.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.10.008</ArticleId><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L. The non-cell-autonomous component of ALS: New in vitro models and future challenges. Biochem. Soc. Trans. 2014;42:1270&#x2013;1274. doi: 10.1042/BST20140168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20140168</ArticleId><ArticleId IdType="pubmed">25233402</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 2018;126:31&#x2013;38. doi: 10.1016/j.neures.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O&#x2019;Banion M.K., Stojanovic K., Sagare A., Boillee S., Cleveland D.W., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008;11:420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Andjus P.R., Batavelji&#x107; D., Vanhoutte G., Mitrecic D., Pizzolante F., Djogo N., Nicaise C., Gankam Kengne F., Gangitano C., Michetti F., et al. In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer&#x2019;s-like disease: MRI approach. Anat. Rec. 2009;292:1882&#x2013;1892. doi: 10.1002/ar.20995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.20995</ArticleId><ArticleId IdType="pubmed">19943341</ArticleId></ArticleIdList></Reference><Reference><Citation>Batavelji&#x107; D., Djogo N., Zupunski L., Baji&#x107; A., Nicaise C., Pochet R., Baci&#x107; G., Andjus P.R. Live monitoring of brain damage in the rat model of amyotrophic lateral sclerosis. Gen. Physiol. Biophys. 2009;28:212&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">19893103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph. Lateral Scler. 2009;10:53&#x2013;57. doi: 10.1080/17482960802521126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802521126</ArticleId><ArticleId IdType="pubmed">18985466</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>